Man Group
DYN icon

Man Group’s Dyne Therapeutics DYN Stock Holding History

Man Group’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.73M Buy
+95,682
New +$1.65M ﹤0.01% 1630
2025
Q1 		– Sell
-746,463
Closed -$17.6M – 2225
2024
Q4 		$17.6M Buy
746,463
+27,813
+4% +$823K 0.05% 481
2024
Q3 		$25.8M Buy
+718,650
New +$28.6M 0.07% 366

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Man Group's DYN Position: Q1 2026 in Review

Man Group opened a new position in Dyne Therapeutics (DYN) in Q1 2026: 95,682 shares worth $1.73M. The stake represents ﹤0.01% of the portfolio and ranks #1630 among its holdings. This is a return to the name: Man Group previously reported a position in DYN as recently as Q4 2024.

Man Group first reported a position in DYN in Q3 2024 and has held it in 3 quarters since. The position peaked at $25.8M in Q3 2024. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

  • Man Group held 95,682 shares of Dyne Therapeutics worth $1.73M as of Q1 2026.
  • Dyne Therapeutics was a new Man Group position in Q1 2026.
  • Dyne Therapeutics made up ﹤0.01% of Man Group's portfolio in Q1 2026, its #1630 holding.
  • Man Group first reported a position in Dyne Therapeutics in Q3 2024 and has held it in 3 quarters since.
  • Man Group's Dyne Therapeutics position peaked at $25.8M in Q3 2024.
  • 227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on Man Group's 13F filing for Q1 2026, filed 15 May 2026.